Fdera Biotech Receives $13.5M Milestone Payment from Novo Nordisk on July 15

NVO2.97%

According to Fdera Pharmaceutical's announcement, its wholly-owned subsidiary Fdera Biotech received a $13.5 million milestone payment from Novo Nordisk on July 15 (approximately 105 million HKD) for UBT251 Phase II clinical trial success in obesity and overweight indications.

Under the exclusive licensing agreement, Fdera Biotech is eligible to receive up to $1.8 billion in potential milestone payments upon achieving certain development and commercialization milestones, plus tiered royalties based on annual net sales by region.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments